{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:25:08Z","timestamp":1779110708562,"version":"3.51.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT) is a recently described type of lung cancer, presenting as a bulky mass variably involving the mediastinum and the lung in patients with smoking history, and exhibits adverse prognosis. The essential diagnostic immunomorphologic features and typical genomic findings have been described. However, there is a continuing need to catalogue the spectrum of genomic changes underlying the disease, the heterogeneity of antigen expression in order to avoid diagnostic pitfalls, and any variability in patient outcomes. We sought to update the literature on the clinicopathologic and genomic characteristics of thoracic SMARCA4- dUT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched for cases diagnosed in our institution, reviewed clinical data, performed comprehensive genomic analysis, and evaluated immunomorphologic features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four cases (three males and one female) were identified at a median age of 61.5 years (range, 49\u201372 years), all with smoking  history. The series included a patient with limited disease treated with surgery and adjuvant chemotherapy, who remained disease-free over a year after diagnosis, underscoring the importance of lung cancer screening among smokers and the possibility of a subgroup of thoracic SMARCA4-dUT with less aggressive disease. In addition to the known immunophenotypic features of the disease, we identified the expression of FLI (in three out of three cases) and WT-1 (in one of three cases), which are endothelial and mesothelial markers, and are findings to be cognizant of to avoid misdiagnosis as angiosarcoma or mesothelioma, respectively. While the neuroendocrine markers synaptophysin and CD56 were variably expressed in some cases, the expression of INSM1 was absent in all cases. Genomic analysis demonstrated tobacco-related features, including a high median tumor mutation burden and <jats:italic>TP53<\/jats:italic> variants. In this limited series,  mutational signature analysis revealed evidence of SBS87 as the predominant single-base substitution COSMIC signature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our work expands the possible diagnostic antigen expression of thoracic SMARCA4-dUT, contributes to the emerging reports on patients with variant disease presentation, and highlights the need for large-scale genomic studies to determine additional mechanisms of the initiation of carcinogenesis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1601443","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:35:14Z","timestamp":1755668114000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Updating the genomic and clinicopathologic features of thoracic SMARCA4-deficient undifferentiated tumor: a mini-series including a long-term survivor"],"prefix":"10.3389","volume":"15","author":[{"given":"Kenneth","family":"Ofori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie C.","family":"Smithgall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma Salah","family":"Jadalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swikrity","family":"Upadhyay Baskota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Crapanzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh M.","family":"Mansukhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTHO.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.017","article-title":"Introduction to 2021 WHO classification of thoracic tumors","volume":"17","author":"Tsao","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B3","article-title":"Thoracic SMARCA4-deficient undifferentiated tumour In: WHO Classification of Tumours Editorial Board","volume-title":"Thoracic tumours","author":"Yoshida","year":"2021"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTHO.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B5","unstructured":"Recent updates in thoracic SMARCA4-deficient undifferentiated tumor - ClinicalKey"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001188","article-title":"SMARCA4-deficient thoracic sarcomas","volume":"43","author":"Perret","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/MODPATHOL.2017.11","article-title":"Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities","volume":"30","author":"Yoshida","year":"2017","journal-title":"Modern Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic Malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Le Loarer","year":"2015","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/J.SEMDP.2021.06.001","article-title":"Recent updates in thoracic SMARCA4-deficient undifferentiated tumor","volume":"38","author":"Nambirajan","year":"2021","journal-title":"Semin Diagn Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13215","article-title":"Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report","volume":"10","author":"Takada","year":"2019","journal-title":"Wiley Online Library"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100235","article-title":"Conversion surgery for advanced thoracic SMARCA4-deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: A case report","volume":"2","author":"Kunimasa","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14547","article-title":"SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report","volume":"13","author":"Utsumi","year":"2022","journal-title":"Thorac Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz160","article-title":"Long lasting major response to pembrolizumab in a thoracic Malignant rhabdoid-like SMARCA4-deficient tumor","volume":"30","author":"Henon","year":"2019","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2217\/IMT-2019-0142\/ASSET\/IMAGES\/LARGE\/FIGURE3.JPEG","article-title":"Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: A case report","volume":"12","author":"Iijima","year":"2020","journal-title":"Immunotherapy"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.1020875\/BIBTEX","article-title":"Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure","volume":"12","author":"Shi","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/JCP-2022-208385","article-title":"Benchmarking bioinformatics approaches for tumour mutational burden evaluation from a large cancer panel against whole-exome sequencing","volume":"76","author":"Pang","year":"2023","journal-title":"J Clin Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2019.230961","article-title":"Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract","volume":"105","author":"Soderquist","year":"2020","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/BIOINFORMATICS\/BTAA554","article-title":"CoMut: visualizing integrated molecular information with comutation plots","volume":"36","author":"Crowdis","year":"2020","journal-title":"Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13073-018-0539-0\/TABLES\/1","article-title":"MutationalPatterns: Comprehensive genome-wide analysis of mutational processes","volume":"10","author":"Blokzijl","year":"2018","journal-title":"Genome Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1066896919865944\/ASSET\/IMAGES\/LARGE\/10.1177_1066896919865944-FIG3.JPEG","article-title":"SMARCA4-deficient thoracic sarcoma: A case report and review of literature","volume":"28","author":"Stewart","year":"2020","journal-title":"Int J Surg Pathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00432-022-04359-6\/METRICS","article-title":"Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4-deficient thoracic tumors","volume":"149","author":"Luo","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000227","article-title":"Increased FLI-1 expression is associated with poor prognosis in non-small cell lung cancers","volume":"24","author":"Lin","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000916","article-title":"INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity","volume":"41","author":"Rooper","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/APP10010040","article-title":"Immunohistochemical expression of wilms\u2019 Tumor 1 protein in human tissues: from ontogenesis to neoplastic tissues","volume":"10","author":"Parenti","year":"2019","journal-title":"Appl Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKW1121","article-title":"COSMIC: Somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1038\/S41598-023-32499-3","article-title":"Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer","volume":"13","author":"Donker","year":"2023","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/S12931-021-01871-0","article-title":"Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden","volume":"22","author":"van den Heuvel","year":"2021","journal-title":"Respir Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7957","DOI":"10.1038\/s41586-023-05783-5","article-title":"The evolution of lung cancer and impact of subclonal selection in TRACERx","volume":"616","author":"Frankell","year":"2023","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99524-1","article-title":"CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer","volume":"11","author":"Gutiontov","year":"2021","journal-title":"Sci Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1601443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:35:16Z","timestamp":1755668116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1601443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1601443"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1601443","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1601443"}}